Synergistic In Vitro Antiretroviral Activity of a Humanized Monoclonal Anti-CD4 Antibody (TNX-355) and Enfuvirtide (T-20)

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2006-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.00761-05PMID 16723592PMCID PMC1479151
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1.

  2004cited by this paper
• Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

  2003cited by this paper
• Anti-Human Immunodeficiency Virus Interactions of SCH-C (SCH 351125), a CCR5 Antagonist, with Other Antiretroviral Agents In Vitro

  2002cited by this paper
• A Humanized, Nondepleting Anti-CD4 Antibody That Blocks Virus Entry Inhibits Virus Replication in Rhesus Monkeys Chronically Infected with Simian Immunodeficiency Virus

  2002cited by this paper
• Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates.

  2002cited by this paper
• Strong in Vitro Synergy Between the Fusion Inhibitor T‐20 and the CXCR4 Blocker AMD‐3100

  2000cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.

  1998cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

  1998cited by this paper
• A Humanized Form of a CD4-Specific Monoclonal Antibody Exhibits Decreased Antigenicity and Prolonged Plasma Half-Life in Rhesus Monkeys While Retaining Its Unique Biological and Antiviral Properties

  1997cited by this paper
• In Vivo Administration of CD4-Specific Monoclonal Antibody: Effect on Provirus Load in Rhesus Monkeys Chronically Infected with the Simian Immunodeficiency Virus of Macaques

  1995cited by this paper
• In Vivo Administration to Rhesus Monkeys of a CD4-Specific Monoclonal Antibody Capable of Blocking AIDS Virus Replication

  1993cited by this paper
• A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells

  1992cited by this paper
• Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion.

  1992cited by this paper
• Synergism and antagonism in chemotherapy

  1991cited by this paper
• UvA-DARE (Digital Academic Repository) Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

  year unknowncited by this paper

• Expanding Treatment Opportunities: Reviewing the Current State of Injectable Antiretrovirals for Treatment of HIV

  2024cites this paper
• Therapeutic application of monoclonal antibodies: A review

  2024cites this paper
• Current ARTs, Virologic Failure, and Implications for AIDS Management: A Systematic Review

  2023cites this paper
• Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment‐limited individuals living with HIV

  2022cites this paper
• Achieving virological control in pan-resistant HIV-1 infection: A case series

  2022cites this paper
• HIV Drug Resistance in Children and Adolescents: Always a Challenge?

  2021cites this paper
• Therapeutic application of monoclonal antibodies: A review

  2020cites this paper
• Ibalizumab: The First Monoclonal Antibody for the Treatment of HIV-1 Infection

  2020cites this paper
• Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection

  2020cites this paper
• Synthetic routes and structure-activity relationships (SAR) of anti-HIV agents: A key review.

  2019cites this paper
• Investigational drugs in HIV: Pros and cons of entry and fusion inhibitors (Review).

  2019cites this paper
• Octadecyloxyethyl benzyl tenofovir: A novel tenofovir diester provides sustained intracellular levels of tenofovir diphosphate.

  2019cites this paper
• Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection

  2019cites this paper
• Anti-retroviral drugs: current state and development in the next decade

  2018cites this paper
• New Mechanism for Release of Endosomal Contents: Osmotic Lysis via Nigericin-Mediated K+/H+ Exchange.

  2018cites this paper
• Current Status of the Pharmacokinetics and Pharmacodynamics of HIV-1 Entry Inhibitors and HIV Therapy.

  2017cites this paper
• Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy

  2017cites this paper
• Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies

  2016cites this paper
• Protein/peptide‐based entry/fusion inhibitors as anti‐HIV therapies: challenges and future direction

  2016cites this paper
• Monoclonal antibodies to host cellular receptors for the treatment and prevention of HIV-1 infection

  2015cites this paper
• Molecular insights into the inhibition of HIV-1 infection using a CD4 domain-1-specific monoclonal antibody.

  2015cites this paper
• Anti-CD4 Monoclonal Antibody Ibalizumab Exhibits Breadth and Potency Against HIV-1, With Natural Resistance Mediated by the Loss of a V5 Glycan in Envelope

  2013cites this paper
• HIV-2 susceptibility to entry inhibitors.

  2013cites this paper
• Inhibitors of HIV-1 entry and integration: recent developments and impact on treatment.

  2013cites this paper
• Closing the door to human immunodeficiency virus

  2013cites this paper
• Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity

  2013cites this paper
• HIV-1 entry inhibitors: recent development and clinical use.

  2013cites this paper
• A Novel Class of Anti-HIV Agents with Multiple Copies of Enfuvirtide Enhances Inhibition of Viral Replication and Cellular Transmission In Vitro

  2012cites this paper
• Peptide Inhibition of HIV-1

  2012cites this paper
• The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment.

  2011cites this paper
• Loss of Asparagine-Linked Glycosylation Sites in Variable Region 5 of Human Immunodeficiency Virus Type 1 Envelope Is Associated with Resistance to CD4 Antibody Ibalizumab

  2011cites this paper
• Immunotherapeutic restoration in HIV-infected individuals.

  2011cites this paper
• Synthetic antibodies targeting HIV-1 infectivity

  2011cites this paper
• Structural study of HIV-1 integrase inhibition by quinolones: contribution to the rational design of new inhibitors

  2011cites this paper
• HIV-1 Entry, Inhibitors, and Resistance

  2010cites this paper
• Epitope Mapping of Ibalizumab, a Humanized Anti-CD4 Monoclonal Antibody with Anti-HIV-1 Activity in Infected Patients

  2010cites this paper
• Antibody Engineering as Opportunity for Selection and Optimization of Anti- HIV Therapeutic Agents

  2010cites this paper
• Host proteins involved in HIV infection: new therapeutic targets.

  2010cites this paper
• Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection.

  2010cites this paper
• ANTI-HIV AGENTS: A STEP TOWARDS FUTURE

  2010cites this paper
• Inhibitors of viral entry.

  2009cites this paper
• CD4-anchoring HIV-1 Fusion Inhibitor with Enhanced Potency and in Vivo Stability*

  2009cites this paper
• HIV-1 entry inhibitors: an overview

  2009cites this paper
• Entry Inhibitors of Human Immunodeficiency Virus

  2009cites this paper
• HIV/AIDS: recent advances in antiretroviral agents.

  2009cites this paper
• New Macrocyclic Amines Showing Activity as HIV Entry Inhibitors Against Wild Type and Multi-Drug Resistant Viruses†

  2009influential citation
• Novel Targets for Antiretroviral Therapy

  2009cites this paper
• Novel Compounds for the Treatment of HIV Type-1 Infection

  2009cites this paper
• Novel targets for anti-retroviral therapy.

  2009cites this paper
• Peptide inhibition of HIV-1: current status and future potential.

  2008cites this paper
• Short communication: In vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV Type 1 gp41.

  2008cites this paper
• Antibodies for HIV treatment and prevention: window of opportunity?

  2008cites this paper
• Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection.

  2007cites this paper
• In Vitro Pre- and Post-Exposure Prophylaxis Using HIV Inhibitors as Microbicides Against Cell-Free or Cell-Associated HIV-1 Infection

  2007influential citation
• Antiviral drugs in the treatment of AIDS: what is in the pipeline ?

  2007cites this paper
• VARIATIONS IN THE V3 CROWN OF HIV-1 ENVELOPE IMPACT AFFINITY FOR CCR5 AND AFFECT ENTRY AND REPLICATIVE FITNESS

  2007cites this paper
• The effect of adaptive and innate immune response on HIV-1 entry and replication

  2007cites this paper
• Enfuvirtide: from basic science to FDA approval

  2007cites this paper
• Microbicides and other topical agents in the prevention of HIV and sexually transmitted infections

  2007cites this paper
• Resistance and HIV infection : resistance development against two new drug candidates and natural variability of the cofactor LEDGF/p75

  2007cites this paper
• Targeting protein-protein interactions for HIV therapeutics

  2007cites this paper
• Immunobiological aspects of therapeutic antibodies and related characterization approaches.

  2007cites this paper
• Novel antiretroviral agents in HIV therapy

  2006cites this paper
• In Vitro Synergy between Peptides or Neutralizing Antibodies Targeting the N-and C-Terminal Heptad Repeats of HIV Type 1 gp41

  year unknowncites this paper